Based on Your Reading:
Get a Mesothelioma Treatment Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
CTLA-4 and Mesothelioma
Table Of Contents
CTLA-4 is a protein that plays an important role in the immune system. It helps keep the immune system in check by regulating T cells. Ipilimumab (Yervoy) and tremelimumab are two immune checkpoint inhibitor drugs that block CTLA-4 to allow T cells to find and fight cancers such as mesothelioma.
Written by Karen Selby, RN | Medically Reviewed By Dr. Andrea Wolf | Edited By Walter Pacheco | Last Update: August 6, 2024
CTLA-4 is a protein receptor on T cells that activates when the body needs to decrease immune system activity.
"Most helpful, steered us in the right direction for treatment. Great source of information and support, the Center followed through on every one of our requests...." see more
Elaine C.
Mesothelioma Patient
"Because of their guidance, I was able to navigate getting my mother into MD Anderson when her case got put aside by mistake in all the COVID-19 craziness. Vanes...." see more
Deanna B.
Daughter of a Mesothelioma Patient
"Hearing the news about my mother's diagnosis was heartbreaking. I felt lost, I didn't know how I could help or where to seek the best medical care. I started re...." see more
Danielle W.
Daughter of a Mesothelioma Patient
"My son Carlos was diagnosed with this terrible and unknown disease a few months ago. Thank God we found The Mesothelioma Center along the way, and Vanessa Blanc...." see more
Martha M.
Mother of a Mesothelioma Patient
"Extremely communicative and helped my dad get an appointment with one of the top centers in Philadelphia. I'm so grateful for this center. They assisted with in...." see more
Sunni H.
Loved One of a Mesothelioma Patient
"Danielle DiPietro was an invaluable resource for me. Her suggestions and recommendations guided us towards stellar practitioners in our area. Without her advoca...." see more
Deborah C.
Spouse of a Mesothelioma Patient
"I was very grateful and appreciative of Dr. Smart from The Mesothelioma Center. She was very helpful to my husband and me. She educated and walked us through th...." see more
Kimberlin C.
Spouse of a Mesothelioma Patient
"In January of 2016, my husband was diagnosed with peritoneal mesothelioma. Our first reaction was: what is this and what can we do? He was diagnosed by an oncol...." see more
Gloria R.
Spouse of a Mesothelioma Patient
Written by Karen Selby, RN | Medically Reviewed By Dr. Andrea Wolf | Edited By Walter Pacheco | Last Update: August 6, 2024
What Is CTLA-4?
Cytotoxic T-lymphocyte-associated protein 4, or CTLA-4, is a protein on the surface of T cells that functions as an immune checkpoint. It affects how T cells recognize cancer cells.
T cells attack foreign invaders, such as viruses and cancer cells.
CTLA-4 prevents T cells from attacking healthy parts of the body, but it can also prevent T cells from identifying and killing cancer cells.
Drugs that block CTLA-4 are called immune checkpoint inhibitors. These drugs have the potential to help people live longer with mesothelioma cancer.
Targeting CTLA-4 with immune checkpoint inhibitors is a form of immunotherapy. New immunotherapies are among the most promising mesothelioma treatments in development right now.
How CTLA-4 Works?
French researchers discovered CTLA-4 in 1987. Nearly a decade later, scientists at the University of California, Berkley, realized the role of CTLA-4.
The protein acts as a break, stopping T cells from attacking cancer cells. Researchers call this breaking mechanism an immune checkpoint.
Immune checkpoints work like on and off switches, activating or deactivating the parts of the immune system.
When activated, CTLA-4 downregulates the immune system by stopping T cells from finding cancer cells. In 2021, a clinical research study concluded that patients who express higher levels of CTLA-4 may have decreased mesothelioma survival times.
Scientists have developed drugs to block and deactivate CTLA-4 — a process commonly called a CTLA-4 blockade — which allows T cells to find and attack cancer cells. These drugs are known as immune checkpoint inhibitors.
he CTLA-4 blockade involves an inhibitor antibody that prevents the slowdown of anti-cancer T cell activation.
Other immune checkpoint inhibitors targeted in mesothelioma treatment include PD-1 and PD-L1. Drugs that target these checkpoints include Keytruda (Pembrolizumab), Opdivo (Nivolumab) and Imfinzi (Durvalumab).
What Drugs Target CTLA-4?
Two checkpoint inhibitor drugs work against CTLA-4: Yervoy and tremelimumab.
Yervoy is FDA-approved to treat late-stage melanoma. Tremelimumab is not FDA-approved, but in 2015 it received orphan drug designation to encourage research into it.
Anti-CTLA-4 Immunotherapy for Mesothelioma
Most of the mesothelioma clinical trials involving Yervoy and tremelimumab combine them with immune checkpoint inhibitors that target other proteins. Studies show that targeting PD-1 and CTLA-4 together increases effectiveness.
Mesothelioma researchers use the combination approach because it has proven more effective in melanoma treatment. For example, when used alone, about 11 percent of melanoma patients respond to Yervoy.
When the anti-PD-1 drug Opdivo is added to Yervoy, about 61% of melanoma patients respond.
Researchers found that adding Opdivo to Yervoy increases the response rate in mesothelioma patients. 2017 French researchers announced a significant improvement in response rates at the 2017 ASCO Annual Meeting.
Approximately 44% of mesothelioma patients had control of their cancer with Opdivo alone, while 50% had control of their cancer using Yervoy combined with Opdivo.
These results justified a phase III trial of Yervoy and Opdivo in mesothelioma patients, which began in 2017.
Less research is available on tremelimumab than Yervoy, but preliminary results show further research is warranted.
Clinical trials are investigating tremelimumab among mesothelioma patients in the U.S.
- One involves combining tremelimumab with surgery.
- Another is combining tremelimumab with durvalumab (Imfinzi).
Clinical trials suggest that Yervoy and tremelimumab are effective for some people with mesothelioma. Further research is necessary to determine which mesothelioma patients may benefit the most from immune checkpoint inhibitors that target CTLA-4.
Additional research is also required to see which drug combinations work best among people with mesothelioma.
This Page Contains 11 Cited Articles
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
- Yu, M. et al. (2021, February). The impact of CD8 and CTLA-4 expression on histopathological character and survival in mesothelioma. Retrieved from https://europepmc.org/article/med/33691360
- ams, W.T., Johnson, D. & Lovly, C.M. (2015, October 29). CTLA-4 Inhibition and CTLA-4 Inhibitors. Retrieved from https://www.mycancergenome.org/content/drug-class/ctla4-inhibition-and-inhibitors
- Dana-Farber Cancer Institute. (2017, May 22). What Is CTLA-4 and How Does it Work in Treating Metastatic Melanoma? Retrieved from http://blog.dana-farber.org/insight/2015/12/what-is-ctla-4-and-how-does-it-work-in-treating-metastatic-melanoma/
- Guazzelli, A. et al. (2017). Anti-CTLA-4 therapy for malignant mesothelioma. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28231719
- Calabro, L. et al. (2015). CTLA4 blockade in mesothelioma: Finally a competing strategy over cytotoxic/target therapy? Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25233793
- Thomas, A. & Hassan, R. (2017). CTLA-4 blockade in mesothelioma: Ineffective or reason for optimism? Retrieved from https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30511-9/fulltext
- Burt, B. (2015). CTLA4 blockade in patients with malignant mesothelioma. Retrieved from http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00110-1/fulltext
- Roncella, S. et al. (2016). CTLA-4 in mesothelioma patients: Tissue expression, body fluid levels and possible relevance as a prognostic factor. Retrieved from https://link.springer.com/article/10.1007/s00262-016-1844-3
- McCoy, K.D. & Gros, G.L. (1999). The role of CTLA-4 in the regulation of T cell immune responses. Retrieved from https://www.nature.com/articles/icb19991
- Scherpereel, A. et al. (2017, June 5). Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. Retrieved from https://meetinglibrary.asco.org/record/145342/abstract
- ClinicalTrials.gov. (2018, January 19). A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma. Retrieved from https://www.clinicaltrials.gov/ct2/show/NCT03075527
Get Your Free Mesothelioma Treatment Guide
Mesothelioma & Immunotherapy Webinar
Immunotherapy & Mesothelioma Clinical Trials
